Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed JournalsGlobeNewsWire • 03/30/23
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual MeetingGlobeNewsWire • 03/30/23
New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's DiseaseGlobeNewsWire • 03/29/23
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALSGlobeNewsWire • 03/23/23
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the diseaseCNBC • 03/22/23
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the diseaseCNBC • 03/20/23
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing ProtectionGlobeNewsWire • 03/16/23
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of DirectorsGlobeNewsWire • 03/08/23
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for ZuranoloneBusiness Wire • 03/08/23